Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis
Abstract Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing medications for multiple sclerosis were far from satisfactory due to their failure to suppress relapses and alleviate disease progression....
Gespeichert in:
| Veröffentlicht in: | Brain (London, England : 1878) Jg. 146; H. 8; S. 3364 - 3372 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
US
Oxford University Press
01.08.2023
|
| Schlagworte: | |
| ISSN: | 0006-8950, 1460-2156, 1460-2156 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Abstract
Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing medications for multiple sclerosis were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for multiple sclerosis prevention are still needed.
We performed Mendelian randomization to explore potential drug targets for multiple sclerosis using summary statistics from the International Multiple Sclerosis Genetics Consortium (nCase = 47 429, nControl = 68 374) and further replicated in UK Biobank (nCase = 1356, nControl = 395 209) and FinnGen cohorts (nCase = 1326, nControl = 359 815). Genetic instruments for 734 plasma and 154 CSF proteins were obtained from recently published genome-wide association studies. The reverse causality detection using bidirectional Mendelian randomization analysis and Steiger filtering, Bayesian co-localization, and phenotype scanning that searched previously reported genetic variant–trait associations were implemented to consolidate the Mendelian randomization findings further. In addition, the protein–protein interaction network was performed to reveal potential associations among proteins and/or present multiple sclerosis medications.
At Bonferroni significance (P < 5.63 × 10−5), Mendelian randomization analysis revealed six protein–multiple sclerosis pairs. In plasma, per standard deviation increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratios for the proteins above were 0.83 (95% CI, 0.79–0.89), 0.59 (95% CI, 0.48–0.71) and 0.88 (95% CI, 0.83–0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42–7.41) increased the risk of multiple sclerosis, while SLAMF7 (OR, 0.42; 95% CI, 0.29–0.60) and CD5L (OR, 0.30; 95%CI, 0.18–0.52) decreased the risk. None of the six proteins had reverse causality. Bayesian co-localization suggested that FCRL3 [coloc.abf-posterior probability of hypothesis 4 (PPH4) = 0.889], TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930) and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with multiple sclerosis. FCRL3, TYMP and SLAMF7 interacted with target proteins of current multiple sclerosis medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts.
Our integrative analysis suggested that genetically determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1 and SLAMF7 had causal effects on multiple sclerosis risk. These findings suggested those five proteins might be promising drug targets for multiple sclerosis and warrant further clinical investigation, especially FCRL3 and SLAMF7.
Lin et al. use Mendelian randomization analysis to search for drug targets for multiple sclerosis, particularly progressive multiple sclerosis. They identify three plasma proteins and two CSF proteins whose genetically determined levels are associated with multiple sclerosis risk, and which may be promising drug targets. |
|---|---|
| AbstractList | Abstract
Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing medications for multiple sclerosis were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for multiple sclerosis prevention are still needed.
We performed Mendelian randomization to explore potential drug targets for multiple sclerosis using summary statistics from the International Multiple Sclerosis Genetics Consortium (nCase = 47 429, nControl = 68 374) and further replicated in UK Biobank (nCase = 1356, nControl = 395 209) and FinnGen cohorts (nCase = 1326, nControl = 359 815). Genetic instruments for 734 plasma and 154 CSF proteins were obtained from recently published genome-wide association studies. The reverse causality detection using bidirectional Mendelian randomization analysis and Steiger filtering, Bayesian co-localization, and phenotype scanning that searched previously reported genetic variant–trait associations were implemented to consolidate the Mendelian randomization findings further. In addition, the protein–protein interaction network was performed to reveal potential associations among proteins and/or present multiple sclerosis medications.
At Bonferroni significance (P < 5.63 × 10−5), Mendelian randomization analysis revealed six protein–multiple sclerosis pairs. In plasma, per standard deviation increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratios for the proteins above were 0.83 (95% CI, 0.79–0.89), 0.59 (95% CI, 0.48–0.71) and 0.88 (95% CI, 0.83–0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42–7.41) increased the risk of multiple sclerosis, while SLAMF7 (OR, 0.42; 95% CI, 0.29–0.60) and CD5L (OR, 0.30; 95%CI, 0.18–0.52) decreased the risk. None of the six proteins had reverse causality. Bayesian co-localization suggested that FCRL3 [coloc.abf-posterior probability of hypothesis 4 (PPH4) = 0.889], TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930) and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with multiple sclerosis. FCRL3, TYMP and SLAMF7 interacted with target proteins of current multiple sclerosis medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts.
Our integrative analysis suggested that genetically determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1 and SLAMF7 had causal effects on multiple sclerosis risk. These findings suggested those five proteins might be promising drug targets for multiple sclerosis and warrant further clinical investigation, especially FCRL3 and SLAMF7.
Lin et al. use Mendelian randomization analysis to search for drug targets for multiple sclerosis, particularly progressive multiple sclerosis. They identify three plasma proteins and two CSF proteins whose genetically determined levels are associated with multiple sclerosis risk, and which may be promising drug targets. Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing medications for multiple sclerosis were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for multiple sclerosis prevention are still needed. We performed Mendelian randomization to explore potential drug targets for multiple sclerosis using summary statistics from the International Multiple Sclerosis Genetics Consortium (nCase = 47 429, nControl = 68 374) and further replicated in UK Biobank (nCase = 1356, nControl = 395 209) and FinnGen cohorts (nCase = 1326, nControl = 359 815). Genetic instruments for 734 plasma and 154 CSF proteins were obtained from recently published genome-wide association studies. The reverse causality detection using bidirectional Mendelian randomization analysis and Steiger filtering, Bayesian co-localization, and phenotype scanning that searched previously reported genetic variant-trait associations were implemented to consolidate the Mendelian randomization findings further. In addition, the protein-protein interaction network was performed to reveal potential associations among proteins and/or present multiple sclerosis medications. At Bonferroni significance (P < 5.63 × 10-5), Mendelian randomization analysis revealed six protein-multiple sclerosis pairs. In plasma, per standard deviation increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratios for the proteins above were 0.83 (95% CI, 0.79-0.89), 0.59 (95% CI, 0.48-0.71) and 0.88 (95% CI, 0.83-0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42-7.41) increased the risk of multiple sclerosis, while SLAMF7 (OR, 0.42; 95% CI, 0.29-0.60) and CD5L (OR, 0.30; 95%CI, 0.18-0.52) decreased the risk. None of the six proteins had reverse causality. Bayesian co-localization suggested that FCRL3 [coloc.abf-posterior probability of hypothesis 4 (PPH4) = 0.889], TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930) and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with multiple sclerosis. FCRL3, TYMP and SLAMF7 interacted with target proteins of current multiple sclerosis medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts. Our integrative analysis suggested that genetically determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1 and SLAMF7 had causal effects on multiple sclerosis risk. These findings suggested those five proteins might be promising drug targets for multiple sclerosis and warrant further clinical investigation, especially FCRL3 and SLAMF7. Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing medications for multiple sclerosis were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for multiple sclerosis prevention are still needed. We performed Mendelian randomization to explore potential drug targets for multiple sclerosis using summary statistics from the International Multiple Sclerosis Genetics Consortium (nCase = 47 429, nControl = 68 374) and further replicated in UK Biobank (nCase = 1356, nControl = 395 209) and FinnGen cohorts (nCase = 1326, nControl = 359 815). Genetic instruments for 734 plasma and 154 CSF proteins were obtained from recently published genome-wide association studies. The reverse causality detection using bidirectional Mendelian randomization analysis and Steiger filtering, Bayesian co-localization, and phenotype scanning that searched previously reported genetic variant-trait associations were implemented to consolidate the Mendelian randomization findings further. In addition, the protein-protein interaction network was performed to reveal potential associations among proteins and/or present multiple sclerosis medications. At Bonferroni significance (P < 5.63 × 10-5), Mendelian randomization analysis revealed six protein-multiple sclerosis pairs. In plasma, per standard deviation increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratios for the proteins above were 0.83 (95% CI, 0.79-0.89), 0.59 (95% CI, 0.48-0.71) and 0.88 (95% CI, 0.83-0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42-7.41) increased the risk of multiple sclerosis, while SLAMF7 (OR, 0.42; 95% CI, 0.29-0.60) and CD5L (OR, 0.30; 95%CI, 0.18-0.52) decreased the risk. None of the six proteins had reverse causality. Bayesian co-localization suggested that FCRL3 [coloc.abf-posterior probability of hypothesis 4 (PPH4) = 0.889], TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930) and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with multiple sclerosis. FCRL3, TYMP and SLAMF7 interacted with target proteins of current multiple sclerosis medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts. Our integrative analysis suggested that genetically determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1 and SLAMF7 had causal effects on multiple sclerosis risk. These findings suggested those five proteins might be promising drug targets for multiple sclerosis and warrant further clinical investigation, especially FCRL3 and SLAMF7.Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing medications for multiple sclerosis were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for multiple sclerosis prevention are still needed. We performed Mendelian randomization to explore potential drug targets for multiple sclerosis using summary statistics from the International Multiple Sclerosis Genetics Consortium (nCase = 47 429, nControl = 68 374) and further replicated in UK Biobank (nCase = 1356, nControl = 395 209) and FinnGen cohorts (nCase = 1326, nControl = 359 815). Genetic instruments for 734 plasma and 154 CSF proteins were obtained from recently published genome-wide association studies. The reverse causality detection using bidirectional Mendelian randomization analysis and Steiger filtering, Bayesian co-localization, and phenotype scanning that searched previously reported genetic variant-trait associations were implemented to consolidate the Mendelian randomization findings further. In addition, the protein-protein interaction network was performed to reveal potential associations among proteins and/or present multiple sclerosis medications. At Bonferroni significance (P < 5.63 × 10-5), Mendelian randomization analysis revealed six protein-multiple sclerosis pairs. In plasma, per standard deviation increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratios for the proteins above were 0.83 (95% CI, 0.79-0.89), 0.59 (95% CI, 0.48-0.71) and 0.88 (95% CI, 0.83-0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42-7.41) increased the risk of multiple sclerosis, while SLAMF7 (OR, 0.42; 95% CI, 0.29-0.60) and CD5L (OR, 0.30; 95%CI, 0.18-0.52) decreased the risk. None of the six proteins had reverse causality. Bayesian co-localization suggested that FCRL3 [coloc.abf-posterior probability of hypothesis 4 (PPH4) = 0.889], TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930) and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with multiple sclerosis. FCRL3, TYMP and SLAMF7 interacted with target proteins of current multiple sclerosis medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts. Our integrative analysis suggested that genetically determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1 and SLAMF7 had causal effects on multiple sclerosis risk. These findings suggested those five proteins might be promising drug targets for multiple sclerosis and warrant further clinical investigation, especially FCRL3 and SLAMF7. |
| Author | Xu, Yan Zhou, Jiawei Lin, Jianfeng |
| Author_xml | – sequence: 1 givenname: Jianfeng orcidid: 0000-0002-0181-5899 surname: Lin fullname: Lin, Jianfeng – sequence: 2 givenname: Jiawei surname: Zhou fullname: Zhou, Jiawei – sequence: 3 givenname: Yan surname: Xu fullname: Xu, Yan email: xuyanpumch@hotmail.com |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36864689$$D View this record in MEDLINE/PubMed |
| BookMark | eNpFkDtPwzAUhS0Eog8YWZFHloAdO04yIsRLAsEAc3QT37RGjl1sR6j8elooMJ3hfOcM34zsO--QkBPOzjmrxUUbwLgL-ADNSrZHplwqluW8UPtkyhhTWVUXbEJmMb4xxqXI1SGZCFUpqap6SuDZJ3TJgKU6jAuaICwwRdr7QIfRJrOySGNnMfhoIjV6C_cGNU3L4MfFkj6i02gNOBrAaT-YT0jGOwoO7HqzOSIHPdiIx7uck9eb65eru-zh6fb-6vIh62TOU4a1gg5RFFy20Le8q3jRlVgWVQ49w0LJSrdaaiVBtqLoa40lAu86pkTLi1bMydnP7yr49xFjagYTO7QWHPoxNnlZCVmruhQb9HSHju2AulkFM0BYN79a_r_8uPprOWu2xptv483OuPgCGYR4IA |
| CitedBy_id | crossref_primary_10_1093_brain_awad295 crossref_primary_10_3389_fphar_2024_1448308 crossref_primary_10_1073_pnas_2425537122 crossref_primary_10_3389_fnagi_2024_1377719 crossref_primary_10_1007_s12672_025_02237_4 crossref_primary_10_1016_j_jad_2024_02_063 crossref_primary_10_1002_acn3_52033 crossref_primary_10_1038_s41467_024_49782_0 crossref_primary_10_1097_SHK_0000000000002465 crossref_primary_10_3390_nu15224787 crossref_primary_10_1097_JS9_0000000000000922 crossref_primary_10_1177_20420188251343140 crossref_primary_10_1186_s12885_024_12376_6 crossref_primary_10_1002_hsr2_70528 crossref_primary_10_21597_jist_1402305 crossref_primary_10_3389_fendo_2024_1448314 crossref_primary_10_3389_fimmu_2024_1412298 crossref_primary_10_2337_db24_0262 crossref_primary_10_1016_j_jnha_2024_100325 crossref_primary_10_1007_s10157_024_02566_8 crossref_primary_10_1016_j_metabol_2025_156339 crossref_primary_10_1186_s13098_025_01712_w crossref_primary_10_1016_j_ecoenv_2023_115896 crossref_primary_10_3389_fimmu_2024_1394438 crossref_primary_10_1080_17512433_2023_2292605 crossref_primary_10_1089_met_2024_0030 crossref_primary_10_1016_j_ijbiomac_2024_139394 crossref_primary_10_3389_fpsyt_2024_1375209 crossref_primary_10_1111_aji_70063 crossref_primary_10_1007_s10067_024_07136_7 crossref_primary_10_1007_s12672_025_02679_w crossref_primary_10_3389_fnagi_2024_1466799 crossref_primary_10_1080_0886022X_2024_2357246 crossref_primary_10_2147_CCID_S523231 crossref_primary_10_2147_JIR_S463450 crossref_primary_10_1016_j_cyto_2024_156736 crossref_primary_10_1177_03000605241272639 crossref_primary_10_1016_j_jad_2025_01_140 crossref_primary_10_1186_s12931_024_03008_5 crossref_primary_10_2174_0118715303325979241206115417 crossref_primary_10_1016_j_phrs_2025_107662 crossref_primary_10_1016_j_yexcr_2025_114516 crossref_primary_10_1186_s12967_024_05856_7 crossref_primary_10_1016_j_reprotox_2025_108902 crossref_primary_10_1016_j_ibneur_2025_02_011 crossref_primary_10_1038_s42003_024_07403_y crossref_primary_10_3390_genes16050523 crossref_primary_10_1016_j_heliyon_2024_e32406 crossref_primary_10_3389_fendo_2024_1372221 crossref_primary_10_3390_ph18050618 crossref_primary_10_3389_fendo_2024_1371498 crossref_primary_10_1021_acsomega_5c03682 crossref_primary_10_3389_fgene_2025_1631446 crossref_primary_10_3389_fimmu_2025_1533959 crossref_primary_10_1007_s12033_025_01416_6 crossref_primary_10_1186_s12967_023_04525_5 crossref_primary_10_3389_fimmu_2024_1419363 crossref_primary_10_1016_j_jad_2024_04_006 crossref_primary_10_1016_j_archger_2024_105359 crossref_primary_10_1007_s12672_025_03318_0 crossref_primary_10_1016_j_diabres_2025_111987 crossref_primary_10_1016_j_intimp_2024_112051 crossref_primary_10_1186_s41065_025_00374_y crossref_primary_10_3390_biomedicines13081841 crossref_primary_10_1038_s41398_024_03056_x crossref_primary_10_1016_j_nbd_2025_106929 crossref_primary_10_1167_iovs_66_12_24 crossref_primary_10_1186_s10194_025_01999_0 crossref_primary_10_1186_s12864_024_10116_5 crossref_primary_10_1681_ASN_0000000000000379 crossref_primary_10_1002_brb3_70625 crossref_primary_10_3389_fimmu_2024_1428962 crossref_primary_10_1007_s12020_024_03745_z crossref_primary_10_1186_s13062_024_00587_7 crossref_primary_10_1002_clt2_12350 crossref_primary_10_1016_j_isci_2025_112081 crossref_primary_10_2147_IJWH_S491414 crossref_primary_10_1080_0886022X_2025_2542530 crossref_primary_10_1016_j_jid_2024_04_023 crossref_primary_10_1002_pdi3_85 crossref_primary_10_1016_j_pnpbp_2024_111208 crossref_primary_10_1038_s41467_023_42682_9 crossref_primary_10_1016_j_intimp_2024_113927 crossref_primary_10_1080_21645515_2024_2432115 crossref_primary_10_1097_MD_0000000000036781 crossref_primary_10_1016_j_cyto_2025_156945 crossref_primary_10_3389_fimmu_2024_1342912 crossref_primary_10_1038_s41598_024_62069_0 crossref_primary_10_1155_cjgh_1716853 crossref_primary_10_3389_fneur_2024_1437778 crossref_primary_10_1093_hmg_ddae110 crossref_primary_10_1111_exd_70158 crossref_primary_10_1080_01616412_2025_2487867 crossref_primary_10_1186_s12890_025_03751_5 crossref_primary_10_3389_fphar_2024_1443045 crossref_primary_10_1016_j_archger_2024_105412 crossref_primary_10_1038_s41598_024_72281_7 crossref_primary_10_1186_s12014_025_09544_6 crossref_primary_10_1186_s12885_024_12513_1 crossref_primary_10_1016_j_jpha_2025_101295 crossref_primary_10_1155_mi_9648279 crossref_primary_10_1007_s10067_024_07059_3 crossref_primary_10_1016_j_identj_2024_10_006 crossref_primary_10_1038_s41598_024_80697_4 crossref_primary_10_1177_08850666241280385 crossref_primary_10_1007_s13760_024_02613_x crossref_primary_10_1186_s10194_024_01853_9 crossref_primary_10_1038_s41598_025_04470_x crossref_primary_10_1038_s41398_024_03196_0 crossref_primary_10_1002_jcsm_13652 crossref_primary_10_1007_s00240_024_01669_x crossref_primary_10_1016_j_msard_2025_106440 crossref_primary_10_1038_s10038_024_01234_9 crossref_primary_10_1212_NXG_0000000000200226 crossref_primary_10_1016_j_jad_2024_07_135 crossref_primary_10_1186_s13040_024_00405_w crossref_primary_10_3389_fgene_2024_1385293 crossref_primary_10_1016_j_ebiom_2024_105197 crossref_primary_10_1038_s42003_024_06755_9 crossref_primary_10_1007_s40520_024_02812_9 crossref_primary_10_3389_fendo_2024_1416978 crossref_primary_10_3389_fnins_2024_1467562 crossref_primary_10_1186_s12967_024_04892_7 crossref_primary_10_1186_s12916_025_03848_y crossref_primary_10_3390_bioengineering12020126 crossref_primary_10_1007_s00335_025_10124_0 crossref_primary_10_1016_j_atherosclerosis_2025_119110 crossref_primary_10_1186_s12931_024_03086_5 crossref_primary_10_1093_bib_bbaf032 crossref_primary_10_1017_S0033291724001077 crossref_primary_10_1186_s40246_024_00607_7 crossref_primary_10_1186_s12872_024_04209_y crossref_primary_10_1002_wjo2_70038 crossref_primary_10_3389_fmed_2024_1426261 crossref_primary_10_1007_s11064_024_04220_x crossref_primary_10_1038_s41598_024_62178_w crossref_primary_10_1186_s12967_024_06027_4 crossref_primary_10_1016_j_heliyon_2024_e37584 crossref_primary_10_1371_journal_pone_0322098 crossref_primary_10_1016_j_ajhg_2024_10_008 crossref_primary_10_3390_ph18060859 crossref_primary_10_1016_j_heliyon_2024_e32053 crossref_primary_10_1111_jocd_70420 crossref_primary_10_1007_s12031_024_02213_7 crossref_primary_10_3389_fcvm_2023_1126208 crossref_primary_10_1186_s13062_024_00575_x crossref_primary_10_3389_fonc_2024_1407795 crossref_primary_10_12998_wjcc_v12_i26_5937 crossref_primary_10_26599_FSHW_2024_9250212 crossref_primary_10_1093_cercor_bhae506 crossref_primary_10_1097_JS9_0000000000001925 crossref_primary_10_1016_j_waojou_2024_101008 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. 2023 The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. |
| Copyright_xml | – notice: The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. 2023 – notice: The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. |
| DBID | TOX CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/brain/awad070 |
| DatabaseName | Oxford Journals Open Access Collection Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2156 |
| EndPage | 3372 |
| ExternalDocumentID | 36864689 10.1093/brain/awad070 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -E4 -~X .2P .55 .GJ .I3 .XZ .ZR 0R~ 1CY 1TH 23N 2WC 354 3O- 4.4 41~ 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6PF 70D AABZA AACZT AAGKA AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAVLN AAWDT AAWTL AAYJJ ABDFA ABDPE ABEJV ABEUO ABGNP ABIME ABIVO ABIXL ABJNI ABKDP ABLJU ABMNT ABNGD ABNHQ ABNKS ABPIB ABPQP ABPTD ABQLI ABQNK ABSMQ ABUFD ABVGC ABWST ABXVV ABXZS ABZBJ ABZEO ACBNA ACFRR ACGFS ACIWK ACPQN ACPRK ACUFI ACUKT ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEHUL AEJOX AEKPW AEKSI AELWJ AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFQV AFFZL AFGWE AFIYH AFOFC AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGQPQ AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AI. AIJHB AJBYB AJDVS AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX ANFBD APIBT APJGH APWMN AQDSO AQKUS ARIXL ASAOO ASPBG ATDFG ATGXG ATTQO AVNTJ AVWKF AXUDD AYOIW AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BR6 BSWAC BTRTY BVRKM BZKNY C1A C45 CAG CDBKE COF CS3 CXTWN CZ4 DAKXR DFGAJ DIK DILTD DU5 D~K E3Z EBS EE~ EIHJH EJD ELUNK EMOBN ENERS F5P F9B FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MBLQV MBTAY MHKGH ML0 MVM N4W N9A NGC NLBLG NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBFPC OBOKY OCZFY ODMLO OHH OHT OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RNI ROL ROX ROZ RUSNO RW1 RXO RZF RZO TCN TCURE TEORI TJX TLC TMA TOX TR2 VH1 VVN W8F WH7 WOQ X7H X7M XJT XOL YAYTL YKOAZ YQJ YSK YXANX ZCG ZGI ZKB ZKX ZXP ~91 AGORE CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c421t-e96acee3514bafb1c815c7e7582af0e5648dbd4d64a4b35f9de7ea1cc063b15b3 |
| IEDL.DBID | TOX |
| ISICitedReferencesCount | 170 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000974991700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0006-8950 1460-2156 |
| IngestDate | Sat Sep 27 23:36:47 EDT 2025 Mon Jul 21 05:59:54 EDT 2025 Mon Oct 13 07:20:24 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | multiple sclerosis drug target Mendelian randomization |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c421t-e96acee3514bafb1c815c7e7582af0e5648dbd4d64a4b35f9de7ea1cc063b15b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-0181-5899 |
| OpenAccessLink | https://dx.doi.org/10.1093/brain/awad070 |
| PMID | 36864689 |
| PQID | 2783496973 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_2783496973 pubmed_primary_36864689 oup_primary_10_1093_brain_awad070 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-08-01 |
| PublicationDateYYYYMMDD | 2023-08-01 |
| PublicationDate_xml | – month: 08 year: 2023 text: 2023-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | US |
| PublicationPlace_xml | – name: US – name: England |
| PublicationTitle | Brain (London, England : 1878) |
| PublicationTitleAlternate | Brain |
| PublicationYear | 2023 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| SSID | ssj0014326 |
| Score | 2.7098389 |
| Snippet | Abstract
Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However,... Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing... |
| SourceID | proquest pubmed oup |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 3364 |
| SubjectTerms | Bayes Theorem Genome-Wide Association Study Humans Mendelian Randomization Analysis Multiple Sclerosis - drug therapy Multiple Sclerosis - genetics Phenotype Polymorphism, Single Nucleotide - genetics |
| Title | Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36864689 https://www.proquest.com/docview/2783496973 |
| Volume | 146 |
| WOSCitedRecordID | wos000974991700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV07T8MwELagQoiF96M8KiOxRk2cOLFHhKgYaOlQpGyRX0EdSFCTwt_nHLsdKEOXTHYSnU--7_x9vkPogRijGNE0KJkhAeDbKBBGQaqSGEo1C0XqiiS9ZpMJy3M-9ecdzT8UPo-H0vZKGIofocE9YbONKLMOPXvL13RBEnd91ezeGzBOQ19Mc2P2n1tsG2CyCyqjo-1_5xgdeuCIH91Kn6AdU52i_bGnxs-QmNatVf7AGL1YfmAn8W4wgFK8Ug3iBqZCWJw3eK6dTMho7Fv14LE9DbenHhjil64__Q1NLHzdknP0PnqePb0Evn9CoBIStYHhqYAYaLX6UpQyUiyiKjOQIRBRhoamCdNSJzpNRCJjWnJtMiMipQC2yIjK-AL1qroyVwhnkliKNguFsgX3IU-TkjOiyogoDqilj-7BsMWXq5BROGY7LjpbFd5WMGZl9gJ82BITojL1sim6bh885VncR5duPdavisFZkpTx6y2-cIMObDd4p8-7Rb12sTR3aE99t_NmMUC7Wc7gOZmOB537_AKKzMOO |
| linkProvider | Oxford University Press |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Potential+drug+targets+for+multiple+sclerosis+identified+through+Mendelian+randomization+analysis&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=Lin%2C+Jianfeng&rft.au=Zhou%2C+Jiawei&rft.au=Xu%2C+Yan&rft.date=2023-08-01&rft.pub=Oxford+University+Press&rft.issn=0006-8950&rft.eissn=1460-2156&rft.volume=146&rft.issue=8&rft.spage=3364&rft.epage=3372&rft_id=info:doi/10.1093%2Fbrain%2Fawad070&rft.externalDocID=10.1093%2Fbrain%2Fawad070 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-8950&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-8950&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-8950&client=summon |